
M&A & Strategic Deals: Dealmaking Shows New Signs of Life but FTC Scrutiny Casts a Dark Shadow
After a significant lull, M&As in the lab diagnostics space heated up in May, with several key deals announced.
Diagnostic Testing and Emerging Technologies
LAB COMPLIANCE ADVISOR
LABORATORY INDUSTRY REPORT
NATIONAL LAB REPORTER
After a significant lull, M&As in the lab diagnostics space heated up in May, with several key deals announced.
This panel will help laboratory owners make decisions now to be better positioned in the future for a potential sale.
The acquisition of the Johns Hopkins spin out and its liquid biopsy ctDNA test will significantly strengthen Quest’s oncology offerings.
Lucira has fallen on hard times since it secured the first FDA EUA for an at-home COVID-19 test in November 2020.
The biggest story in M&A dealmaking continues to be the deal that’s being undone—Illumina’s acquisition of GRAIL.